Search

Your search keyword '"Allergan PLC -- Product development"' showing total 30 results
Start Over Descriptor "Allergan PLC -- Product development" Journal plus company updates
30 results on '"Allergan PLC -- Product development"'

1. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1|2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genes, Genetic disorders, Genomics, Health, General interest, News, opinion and commentary, Oregon Health & Science University
Abstract

DUBLIN: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Published
2020

2. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical [...]

Published
2020

3. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials [...]

Published
2020

4. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, Periodicals, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the [...]

Published
2019

5. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the [...]

Published
2019

6. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Subjects
Allergan PLC -- Product development, Clinical trials -- Physiological aspects, Macular degeneration -- Physiological aspects, Ranibizumab -- Physiological aspects, Medical research -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Ophthalmology, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: [...]

Published
2019

7. Allergan and Editas Medicine Initiate the Brilliance Phase 1|2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genetic research, Genes, Genetic disorders, Genomics, General interest, News, opinion and commentary
Abstract

Massachusetts: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Published
2019

8. Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Clinical trials, Medical research, Contraceptives -- Product development, Levonorgestrel, Medical societies, Obstetricians, Women's health, Contraceptive drug implants, Health, Physicians, General interest, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

SAN FRANCISCO and DUBLIN: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc [...]

Published
2019

9. Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following news release:Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive 3-month topline results from the second pivotal clinical trial of [...]

Published
2019

10. Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration

Subjects
Allergan PLC -- Product development, Clinical trials, Macular degeneration, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Zurich, Switzerland: SIX Swiss Exchange Ltd has issued the following notice: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing [...]

Published
2018

11. Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
Allergan PLC -- Product development, Clinical trials, Ophthalmic agents -- Product development, Hypertension -- Care and treatment, Pharmaceutical industry -- Product development, Open-angle glaucoma -- Care and treatment, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: - Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on [...]

Published
2018

12. Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

SAN FRANCISCO: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), [...]

Published
2018

13. Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Medical research, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

Dublin: Allergan plc (AGN) has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE II (UBR-MD-02), the second of [...]

Published
2018

14. Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

Dublin: Allergan plc (AGN) has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first [...]

Published
2018

15. Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagoni

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine, General interest, News, opinion and commentary
Abstract

Republic of Ireland: Allergan has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first [...]

Published
2018

16. Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

California: Allergan, Plc has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of [...]

Published
2018

17. Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

Oakland: Allergan has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two [...]

Published
2018

18. Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, General interest, News, opinion and commentary
Abstract

Allergan plc. : Allergan plc. has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the [...]

Published
2018

19. Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Bipolar disorder -- Drug therapy, General interest, News, opinion and commentary
Abstract

Coolock: Allergan Pharmaceutical company has issued the following news release: DUBLIN and BUDAPEST, Hungary, Dec. 18, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Gedeon [...]

Published
2017

20. Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX(r) (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)

Subjects
Allergan PLC -- Product development, Major depressive disorder -- Care and treatment, Botulinum toxins -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Calif: Allergan plc has issued the following news release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced topline data from a Phase II study with Major Depressive [...]

Published
2017

21. Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX(r) (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)

Subjects
Allergan PLC -- Product development, Major depressive disorder -- Care and treatment, Medical research, Botulinum toxins -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Allergan plc.: Allergan plc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced topline data from a Phase II study with Major [...]

Published
2017

22. Allergan to advance Botox trial to third phase for treatment of depression

Subjects
Allergan PLC -- Product development, Clinical trials, Depression (Mood disorder) -- Drug therapy, Botulinum toxins -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Calif: Allergan plc has issued the following news release: Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in [...]

Published
2017

23. Allergan, Paratek's acne drug succeeds in two phase 3 trials

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Acne -- Drug therapy, Pharmaceutical industry -- Product development, Antiacne agents, General interest, News, opinion and commentary
Abstract

Calif: Allergan plc has issued the following news release: Allergan and Paratek Pharmaceuticals' acne drug sarecycline has met its primary efficacy endpoints in two phase 3 trials. The studies have [...]

Published
2017

24. FDA Approves Allergan's sNDA for AVYCAZ(r) (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pyelonephritis, Urinary tract infections, Pharmaceutical industry -- Product development, Drug approval, General interest, News, opinion and commentary, Avycaz (Medication)
Abstract

DUBLIN: Allergan plc has issued the following news release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the [...]

Published
2017

25. FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pyelonephritis, Urinary tract infections, Pharmaceutical industry -- Product development, Drug approval, General interest, News, opinion and commentary, Avycaz (Medication)
Abstract

Allergan plc.: Allergan plc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved [...]

Published
2017

26. Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Subjects
Amgen Inc. -- Product development, Allergan PLC -- Product development, Biotechnology industries -- Product development, Epidermal growth factors, Pharmaceutical industry -- Product development, Breast cancer -- Care and treatment, Trastuzumab -- Product development, General interest, News, opinion and commentary
Abstract

Thousand Oaks: AMGen, Inc has issued the following news release: Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP [...]

Published
2016

27. Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Subjects
Amgen Inc. -- Product development, Allergan PLC -- Product development, Biotechnology industries -- Product development, Epidermal growth factors, Pharmaceutical industry -- Product development, Breast cancer -- Care and treatment, Trastuzumab -- Product development, General interest, News, opinion and commentary
Abstract

Dublin: Amgen Inc. has issued the following news release: Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 [...]

Published
2016

28. Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Subjects
Amgen Inc. -- Product development, Allergan PLC -- Product development, Biotechnology industries -- Product development, Epidermal growth factors, Pharmaceutical industry -- Product development, Breast cancer -- Care and treatment, Trastuzumab -- Product development, General interest, News, opinion and commentary
Abstract

California: Amgen Inc.has issued the following news release Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared [...]

Published
2016

29. Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Dublin:Allergan, Plc has issued the following news release:Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials [...]

Published
2016

30. Ulipristal meets Phase III uterine fibroid endpoints

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

San Carlos, CA: BioCentury has issued the following news release:Allergan plc (NYSE:AGN) and Gedeon Richter Ltd. (Budapest:RICHTER) said ulipristal acetate (PGL4001) met the co-primary and secondary endpoints in the Phase [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results